This article is about a variant of the virus that causes COVID-19. Not to be confused with the Deltacoronavirus grouping of coronavirus species that affects birds and non-human mammals.
The Delta variant (B.1.617.2) was[3][4] a variant of SARS-CoV-2, the virus that causes COVID-19. It was first detected in India on 5 October 2020. The Delta variant was named on 31 May 2021 and had spread to over 179 countries by 22 November 2021. The World Health Organization (WHO) indicated in June 2021 that the Delta variant was becoming the dominant strain globally.[5]
It has mutations in the gene encoding the SARS-CoV-2 spike protein[6] causing the substitutions T478K, P681R and L452R,[7][8] which are known to affect transmissibility of the virus as well as whether it can be neutralised by antibodies for previously circulating variants of the COVID-19 virus.[9] In August 2021, Public Health England (PHE) reported secondary attack rate in household contacts of non-travel or unknown cases for Delta to be 10.8% vis-à-vis 10.2% for the Alpha variant;[10] the case fatality rate for those 386,835 people with Delta is 0.3%, where 46% of the cases and 6% of the deaths are unvaccinated and below 50 years old.[11]Immunity from previous recovery[12][13] or COVID-19 vaccines are effective in preventing severe disease or hospitalisation from infection with the variant.[14]
On 7 May 2021, PHE changed their classification of lineage B.1.617.2 from a variant under investigation (VUI) to a variant of concern (VOC) based on an assessment of transmissibility being at least equivalent to B.1.1.7 (Alpha variant);[15] the UK's SAGE using May data estimated a "realistic" possibility of being 50% more transmissible.[16] On 11 May 2021, the WHO also classified this lineage VOC, and said that it showed evidence of higher transmissibility and reduced neutralisation. On 15 June 2021, the Centers for Disease Control and Prevention (CDC) declared Delta a variant of concern.[17]
^Sivan Gazit (25 August 2021). "Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections". medRxiv10.1101/2021.08.24.21262415v1. The study in Israel tracked 46035 unvaccinated recovered and 46035 vaccinated people of the same age distribution, to compare their infection occurrence in the follow-up period. 640 infections and 21 hospitalization in the vaccinated group and 108 infections and 4 hospitalizations in the recovered group were recorded.